Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK)
HKD 11.12
(0.18%)
HKD 11.12
(0.18%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -41.6 Million CNY | 59.25% |
| 2022 | -86.56 Million CNY | 60.13% |
| 2021 | -199.94 Million CNY | -117.77% |
| 2020 | -90.16 Million CNY | -55.73% |
| 2019 | -58.96 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 29.94 Million CNY | 0.0% |
| 2024 Q1 | 29.94 Million CNY | 222.5% |
| 2023 FY | - CNY | 59.25% |
| 2023 Q2 | -34.58 Million CNY | 0.0% |
| 2023 Q4 | -24.44 Million CNY | 0.0% |
| 2023 Q1 | -34.58 Million CNY | 48.58% |
| 2023 Q3 | -24.44 Million CNY | 29.32% |
| 2022 Q2 | -34.48 Million CNY | 0.0% |
| 2022 FY | - CNY | 60.13% |
| 2022 Q3 | -67.25 Million CNY | -95.02% |
| 2022 Q1 | -34.48 Million CNY | 49.42% |
| 2022 Q4 | -67.25 Million CNY | 0.0% |
| 2021 Q3 | -68.18 Million CNY | -89.08% |
| 2021 Q2 | -36.06 Million CNY | 0.0% |
| 2021 FY | - CNY | -117.77% |
| 2021 Q4 | -68.18 Million CNY | 0.0% |
| 2021 Q1 | -36.06 Million CNY | -22.19% |
| 2020 FY | - CNY | -55.73% |
| 2020 Q3 | -29.51 Million CNY | -86.19% |
| 2020 Q1 | -15.85 Million CNY | 0.0% |
| 2020 Q2 | -15.85 Million CNY | 0.0% |
| 2020 Q4 | -29.51 Million CNY | 0.0% |
| 2019 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Vincent Medical Holdings Limited | 104.43 Million HKD | 139.837% |